ADC Therapeutics SA (ADCT) 2021年年度报告「NYSE」.pdf

1、ADC Therapeutics SA2021 Annual ReportTable of ContentsAnnual Report1Table of ContentsLetter to Shareholders3Business Update5Financial Review72Corporate Governance94Report from the Auditor on the Consolidated IFRS Financial Statements109Consolidated IFRS Financial Statements for the Year Ended Decemb

2、er 31,2021119Report from the Auditor on the Statutory Financial Statements of ADC Therapeutics SA177Statutory Financial Statements of ADC Therapeutics SA for the Year Ended December 31,2021183Report from the Auditor on the Compensation Report of ADC Therapeutics SA197Compensation Report of ADC Thera

3、peutics SA for the Year Ended December 31,2021200Forward Looking Statements216Table of ContentsAnnual Report2Dear Shareholders,2021 was a pivotal year for ADC Therapeutics in which we had many significant achievements across our pipeline and the business.Notably,we secured our first FDA approval and

4、 initiated the launch of ZYNLONTA to patients in need,we advanced our promising pipeline of hematologic and solid tumor programs in multiple clinical and preclinical studies,and we made significant strides in our corporate development.I would like to thank our dedicated employees and all the physici

5、ans and patients working together to bring these innovative medicines to patients.The approval of ZYNLONTA in April 2021 for patients with relapsed or refractory diffuse large B-cell lymphoma(DLBCL),just five years after dosing the first patient,was the highlight of the year.It validated our proprie

6、tary antibody drug conjugate(ADC)platform and brought a new treatment option to patients with significant medical need,including those who had failed other treatment regimens such as CAR-T therapy and stem cell transplant.Our world-class commercial team executed the launch flawlessly in the hybrid C